Treasury and IRS Signal Major Tax Relief Is Coming for Medical Cannabis Businesses

For years, cannabis operators have filed their taxes with a knot in their stomachs. Section 280E of the federal tax code — written in 1982 to punish drug traffickers, never revised, never updated — has quietly functioned as a sledgehammer against legal cannabis businesses. Dispensaries, cultivators, and processors across 38 states have been prohibited from deducting standard business expenses, effectively taxed on gross revenue rather than profit. It has shuttered companies, stalled expansion, and kept the legal market perpetually in debt to a federal government that doesn’t even recognize its existence.

Now, something is shifting. The Treasury Department and the Internal Revenue Service issued a joint press release this week stating they “expect DOJ’s action to have significant positive tax consequences for businesses in the medical marijuana industry.” The language is measured, cautious, bureaucratic — but for an industry that has spent a decade begging Washington to notice its existence, it lands like a thunderclap.

What Treasury Actually Said — and What It Didn’t

The joint release is short on specifics. Treasury and the IRS say tax guidance is “forthcoming” for state-licensed medical cannabis businesses, tying that expectation directly to recent Department of Justice action on cannabis scheduling. They have not released the guidance itself, have not specified a timeline, and have not indicated whether the relief will be retroactive. What they have done is acknowledge, in an official government communication, that the current tax treatment of medical cannabis businesses is expected to change.

That’s new. That’s meaningful. And cannabis operators across the country are parsing every word.

The DOJ action at the center of Treasury’s statement is the Trump administration’s move toward partial rescheduling — a process that The Guardian described last week as already creating confusion among industry observers and legal experts. The rescheduling effort, which would move cannabis from Schedule I to Schedule III under the Controlled Substances Act, has proceeded in partial, piecemeal fashion, leading experts to warn that the regulatory and tax landscape may become “more complex before it becomes clearer.”

Still, even partial rescheduling has real consequences under 280E. The provision explicitly applies to Schedule I and II substances. If cannabis clears Schedule III status for medical use — even incompletely, even with caveats — the legal basis for applying 280E to licensed medical cannabis businesses may effectively collapse.

280E: A Slow-Motion Crisis the Industry Knows Too Well

To understand why this week’s announcement matters, you have to understand what 280E has actually done to legal cannabis businesses over the past decade.

A standard business can deduct rent, payroll, marketing, insurance, utilities. A cannabis dispensary cannot — not federally. Because cannabis remains a controlled substance under federal law, 280E classifies legal cannabis retailers as drug traffickers for tax purposes, stripping them of normal deductions. The effective tax rates facing cannabis businesses have routinely run between 50 and 80 percent. Some profitable-on-paper companies have owed more in federal taxes than they earned in net income.

The burden has not fallen equally. Smaller operators — often minority-owned businesses, equity licensees, legacy-market participants who entered the legal market in good faith — have been disproportionately crushed. Larger multi-state operators (MSOs) have had the accounting infrastructure and legal firepower to navigate 280E creatively. Independent shop owners have often simply gone under.

Social equity programs in states like Illinois, Massachusetts, and California were designed in part to ensure that communities harmed by decades of drug enforcement had a pathway into the legal industry. 280E has functioned as a hidden counterpressure against those same communities — taxing equity licensees at rates that would make most businesses unsustainable.

Trump’s CBD Move: A Second Signal From the Same Week

The Treasury announcement didn’t arrive in a vacuum. On the same day, President Trump posted on social media calling on Congress to loosen federal restrictions on hemp-derived CBD and other cannabinoids, writing that “Hemp-derived CBD has made a HUGE difference for so many people.” NORML covered the post directly. The President’s vocal support for hemp and CBD — consumer-facing, politically popular, low-friction — represents a notable expansion of the administration’s public posture on cannabinoids broadly.

That matters for context. Trump’s team has now signaled movement on cannabis rescheduling, endorsed CBD deregulation, and — through Treasury — indicated that tax consequences are expected to change. Taken together, these are the clearest signs yet that the federal government is preparing to move, even if the exact shape of that movement remains unclear.

Whether the administration will follow through with concrete, enforceable guidance before the political winds shift again is a different question entirely.

The Guidance Still Doesn’t Exist

The central problem with this week’s announcement is that “forthcoming” is not “here.” Treasury and the IRS have not published revised rules, proposed regulations, or a timeline. The cannabis industry has been promised federal movement before — the Biden-era rescheduling process dragged on for years before landing, incomplete, in the final months of the administration. Operators have heard language like this before and watched it evaporate.

What’s different now is political alignment: a Republican president has publicly championed hemp and CBD, the DOJ has moved on scheduling, and Treasury has acknowledged the consequence. The pieces are there. The paper is not.

For state-licensed medical cannabis businesses, the practical advice hasn’t changed: continue working with cannabis-specialized tax counsel, continue planning for 280E obligations, and do not restructure your finances around guidance that has not been published. When the guidance arrives — if it arrives, in enforceable form — the legal and business implications will need to be assessed against whatever it actually says.

But for the first time in a long time, the words “positive tax consequences” appear in a joint release from Treasury and the IRS, referring to cannabis businesses by name. In an industry accustomed to federal silence and federal hostility, that sentence is worth reading twice.

Maya Torres covers national cannabis policy, federal legislation, and the intersection of drug law and social justice for CannabisInquirer.com.